articleThe Lancet OncologyJan 1, 2011Closed access

Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial.

BCB CoiffierEOE.A. OsmanovXHXin HongASAdriana ScheligaJMJiřı́ Mayer

Abstract

No abstract available for this paper.

Citation impact

1,624
total citations
FWCI
39.80
Percentile
100%
References
0
Citations per year

Authors

21

Topics & keywords

Topics
Keywords
  • Medicine
  • Rituximab
  • Bortezomib
  • Follicular lymphoma
  • Oncology
  • Internal medicine
  • Lymphoma
  • Multiple myeloma
UN Sustainable Development Goals
  • Zero hunger
No related works found for this paper.